Ocular immunology and inflammation · 2025
Sunset Glow Fundus and Bilateral Choroidal Neovascularization in a Pediatric Patient Receiving Nivolumab: A Rare Pediatric Immune-Related Ocular Complication.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ozturan Izlem, Kadayifcilar Sibel, Bezci Aygun Figen, Kutluk Tezer
Аннотация
PURPOSE: To report a rare case of immune checkpoint inhibitor (ICI)- associated bilateral choroidal neovascularization (CNV) and sunset glow fundus appearance in a pediatric patient receiving long-term nivolumab therapy.
METHOD: Observational case report.
CASE REPORT: A 15-year-old male with metastatic myoepithelial carcinoma, on nivolumab for 2.5 years, presented with bilateral blurred vision. Fundus examination revealed a sunset glow fundus, punched-out lesions, and CNV in both eyes. Optical coherence tomography (OCT) confirmed inflammatory CNV with choroidal thickening. Nivolumab was discontinued, and the patient received systemic corticosteroids and intravitreal ranibizumab. Despite initial improvement, CNV recurred upon steroid tapering, requiring additional anti-VEGF injections. At four months, vision stabilized with no CNV reactivation.
CONCLUSION: This case represents the first pediatric report of ICI- associated bilateral CNV and sunset glow fundus appearance. It underscores the importance of monitoring for late-onset immune-related ocular complications in patients on long-term nivolumab therapy.
METHOD: Observational case report.
CASE REPORT: A 15-year-old male with metastatic myoepithelial carcinoma, on nivolumab for 2.5 years, presented with bilateral blurred vision. Fundus examination revealed a sunset glow fundus, punched-out lesions, and CNV in both eyes. Optical coherence tomography (OCT) confirmed inflammatory CNV with choroidal thickening. Nivolumab was discontinued, and the patient received systemic corticosteroids and intravitreal ranibizumab. Despite initial improvement, CNV recurred upon steroid tapering, requiring additional anti-VEGF injections. At four months, vision stabilized with no CNV reactivation.
CONCLUSION: This case represents the first pediatric report of ICI- associated bilateral CNV and sunset glow fundus appearance. It underscores the importance of monitoring for late-onset immune-related ocular complications in patients on long-term nivolumab therapy.